SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix
SERB Pharmaceuticals has closed a deal to take over development and commercialization rights to Idefirix (imlifidase) across Europe and MENA from Hansa Biopharma.
SERB Pharmaceuticals has completed its acquisition of the European and Middle East and North Africa development and commercialization rights to Idefirix (imlifidase) from Hansa Biopharma, the company announced via GlobalNewswire. The transaction marks a significant portfolio expansion for SERB as it moves to strengthen its presence in specialty pharmaceutical markets across two major regions.
Idefirix, known generically as imlifidase, is the branded therapy at the center of the deal. By securing these regional rights, SERB positions itself to drive both the ongoing development and the commercial rollout of the drug across European and MENA markets, where specialty therapeutics demand has continued to grow.
Read more Moburst Acquires Hyperzon to Expand Amazon Marketing Capabilities →
The completion of this acquisition signals SERB's broader strategic intent to build out its rare disease and specialty medicine portfolio beyond its existing footprint. Deals of this nature — where a larger commercial operator acquires regional rights from a biotech developer — are increasingly common as mid-sized pharmaceutical firms seek to maximize the geographic reach of approved or late-stage assets without fully divesting global control.
Hansa Biopharma, the Swedish biotech that originally developed imlifidase, retains rights outside the acquired territories, allowing it to continue pursuing its own commercialization strategy in other global markets. The financial terms of the transaction were not disclosed in the announcement.
Continue reading at GlobalNewswire.
